DSAEK rapidly restores corneal clarity in young CHED patients

Article

Descemet-stripping automated endothelial keratoplasty (DSAEK) efficiently restores corneal clarity with minimal complications in young congenital hereditary endothelial dystrophy (CHED) patients

Descemet-stripping automated endothelial keratoplasty (DSAEK) efficiently restores corneal clarity with minimal complications in young congenital hereditary endothelial dystrophy (CHED) patients, according to a study published in the Archives of Ophthalmology.

A team led by Dr Massimo Busin, Villa Serena Hospital, Forlí, Italy, examined the medical records of 15 eyes of 8 CHED patients who underwent DSAEK. A detailed ophthalmic examination of all patients was conducted preoperatively and at each postoperative visit. All patients underwent standard DSAEK, except in patients younger than 12 months. These patients didn't have their Descemet membrane removed.

The mean patient age was 9 years and the average follow-up period was 15.9 months. Graft detachment was found in 4 cases and was treated by rebubbling.

Within 1 week after surgery all corneas were clear. Preoperatively, six eyes were able to fix and follow and 3 eyes could fix and follow 1 week postoperatively. Preoperative best-corrected visual acuity was recorded as 20/200 or less in 6 eyes. Best-corrected visual acuity of 20/40 or better was achieved postoperatively.

The study advises conducting DSAEK at an earlier age in order to provide improved visual development and possibly prevent amblyopia.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.